×
About 10,423 results

ALLMedicine™ Myelodysplastic Syndromes Center

Research & Reviews  2,996 results

Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Ca...
https://www.ncbi.nlm.nih.gov/pubmed/36735715
Alternative Therapies in Health and Medicine; Lin Y, He J et. al.

Feb 4th, 2023 - Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by bone marrow dysplasia, ineffective hematopoiesis, and cytopenias. Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) pat...

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
https://clinicaltrials.gov/ct2/show/NCT05350748

Feb 3rd, 2023 - Background: Myelodysplastic syndromes (MDS) are heterogenous stem cell disorders characterized by ineffective hematopoiesis resulting in cellular dysplasia, peripheral cytopenias, and increased risk for transformation to acute myeloid leukemia (AM...

Luspatercept in combination with recombinant erythropoietin in patients with myelodyspl...
https://doi.org/10.1111/ejh.13933
European Journal of Haematology; Fattizzo B, Versino F et. al.

Feb 3rd, 2023 - Patients with myelodysplastic syndromes and ring sideroblasts (MDS RS) are clinically characterized by severe anemia and transfusion need. Erythropoiesis stimulating agents (ESAs), which stimulates hemoglobin production and early maturation of ery...

Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia.
https://doi.org/10.1097/MOH.0000000000000749
Current Opinion in Hematology; Brunner AM

Feb 3rd, 2023 - Therapies that target the immune system are increasingly used across oncology, including in hematologic malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). While allogeneic transplant has been a key therapy in th...

Molecular landscape of myelodysplastic neoplasms in disease classification and prognost...
https://doi.org/10.1097/MOH.0000000000000752
Current Opinion in Hematology; Maggioni G, Della Porta MG

Feb 3rd, 2023 - The aim of this review is to provide a complete perspective of the evidence that led to the three recent new landmarks of myelodysplastic syndromes (MDS) definition and prognostication: the WHO 2022 and International Consensus Classification (ICC)...

see more →

Guidelines  12 results

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment a...
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Soc... Fenaux P, Haase D et. al.

Nov 23rd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH...
https://doi.org/10.1200/JCO.18.02142
Journal of Clinical Oncology : Official Journal of the Am... Bohlius J, Bohlke K et. al.

Apr 11th, 2019 - To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. PubMed and the Cochrane Library were searched for randomiz...

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Stone RM et. al.

Jan 4th, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811170
Blood Malcovati L, Hellström-Lindberg E et. al.

Aug 28th, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit...

Myelodysplastic syndromes: clinical practice guidelines in oncology.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000017
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Attar E et. al.

Jul 13th, 2013 - The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disord...

see more →

Drugs  45 results see all →

Clinicaltrials.gov  470 results

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
https://clinicaltrials.gov/ct2/show/NCT05350748

Feb 3rd, 2023 - Background: Myelodysplastic syndromes (MDS) are heterogenous stem cell disorders characterized by ineffective hematopoiesis resulting in cellular dysplasia, peripheral cytopenias, and increased risk for transformation to acute myeloid leukemia (AM...

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
https://clinicaltrials.gov/ct2/show/NCT01898793

Feb 1st, 2023 - This phase I/2 trial studies the side effects and best dose of activated natural killer cells in treating patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. Giving chemotherapy before a donor natural killer ...

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
https://clinicaltrials.gov/ct2/show/NCT05568225

Feb 1st, 2023 - The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS.

Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
https://clinicaltrials.gov/ct2/show/NCT05588154

Feb 1st, 2023 - Background: Myelodysplastic syndromes (MDS) are heterogeneous stem cell disorders characterized by ineffective hematopoiesis resulting in cellular dysplasia, peripheral cytopenias, and increased risk for transformation to acute myeloid leukemia (A...

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT01522976

Jan 31st, 2023 - PRIMARY OBJECTIVES: I. To select based on response rate (complete remission, partial remission, or hematologic improvement) either the combination of lenalidomide and azacitidine or the combination of vorinostat and azacitidine for further testing...

see more →

News  638 results

ODAC to Review Lymphoma Drug; Tobacco Control; Artificial Skin Aids Cancer Studies
https://www.medpagetoday.com/hematologyoncology/lymphoma/102854

Jan 27th, 2023 - The FDA announced that the Oncologic Drugs Advisory Committee (ODAC) will meet March 9 to review the accelerated approval of polatuzumab vedotin (Polivy) plus rituximab (Rituxan) and chemotherapy for untreated diffuse large B-cell lymphoma. Jansse...

'Reconstructive Burnout'; Better Brachytherapy for Cervical Ca; Body-Image Distress
https://www.medpagetoday.com/hematologyoncology/breastcancer/102535

Jan 6th, 2023 - Identifying risk factors for "reconstructive burnout" may help reduce the number of patients who begin reconstruction surgery after breast cancer treatment but do not complete the process. (Plastic and Reconstructive Surgery) Individualized brachy...

SOLO-1 Data Support Use of Olaparib Maintenance to Achieve Long-Term Remission in BRCA+ Advanced Ovarian Cancer
https://www.onclive.com/view/solo-1-data-support-use-of-olaparib-maintenance-to-achieve-long-term-remission-in-brca-advanced-ovarian-cancer

Nov 17th, 2022 - Seven-year follow-up data from the phase 3 SOLO-1/GOG-3004 trial (NCT01844986) provide further confirmation of the long-term survival benefit achieved with maintenance treatment with olaparib (Lynparza) vs placebo in patients with newly diagnosed,...

Niraparib Maintenance Produces Long-Term Benefit in Advanced Ovarian Cancer, Irrespective of HRD Status
https://www.onclive.com/view/niraparib-maintenance-produces-long-term-benefit-in-advanced-ovarian-cancer-irrespective-of-hrd-status

Nov 17th, 2022 - Frontline niraparib (Zejula) maintenance sustained a progression-free survival (PFS) benefit in patients with advanced ovarian cancer, according to updated data from the phase 3 PRIMA trial (NCT02655016) presented at the 2022 ESMO Congress. Notab...

PARP Maintenance Therapy Provides Varying Benefit in Advanced Ovarian Cancer
https://www.onclive.com/view/parp-maintenance-therapy-provides-varying-benefit-in-advanced-ovarian-cancer

Nov 10th, 2022 - The benefit of PARP maintenance therapy for patients with advanced ovarian cancer differs depending on a number of factors, including the homologous recombination and BRCA mutation status of the tumor, according to Eirwen M. Miller, MD.1 In a pre...

see more →

Patient Education  8 results see all →